Rate of remission and residual PD signals
| All biologics | TNF inhibitors* | Tocilizumab | Abatacept | |
|---|---|---|---|---|
| Patients number | 94 | 34 | 37 | 23 |
| Residual PD signals** | 33/94 (35.1%) | 9/34 (26.4%) | 15/37 (40.5%) | 9/23 (39.1%) |
| DAS28-CRP remission | ||||
| Achieved*** | 78/94 (83.0%) | 32/34 (94.1%) | 31/37 (83.8%) | 15/23 (65.2%) |
| Residual PD signals | 22/78 (28.2%) | 8/32 (25.0%) | 10/31 (32.3%) | 4/15 (26.7%) |
| DAS28-ESR remission | ||||
| Achieved | 57/94 (68.7%) | 21/34 (72.4%) | 26/37 (78.8%) | 10/23 (47.6%) |
| Residual PD signals | 16/57 (28.1%) | 5/21 (23.8%) | 9/26 (34.6%) | 2/10 (20.0%) |
| CDAI remission | ||||
| Achieved | 59/94 (62.8%) | 26/34 (76.5%) | 23/37 (62.2%) | 10/23 (43.5%) |
| Residual PD signals | 13/59 (22.0%) | 5/26 (19.2%) | 7/23 (30.4%) | 1/10 (10.0%) |
| Boolean remission | ||||
| Achieved | 46/94 (48.9%) | 21/34 (61.8%) | 17/37 (45.9%) | 8/23 (34.8%) |
| Residual PD signals | 10/46 (21.7%) | 5/21 (23.8%) | 4/17 (23.5%) | 1/8 (12.5%) |
*TNF inhibitors (Infliximab (n=6), Etanercept (n=14), Adalimumab (n=7), Golimumab (n=4), Certolizumab pegol (n=3)). ** Residual PD signals: patients who had any PD signals in asessed joints. ***Achieved: remission rate in biologics treated patients who were maintained normal CRP for a half year.